Bone Abstracts

Osteogenesis imperfecta (OI), or brittle bone disease, is a heterogeneous inherited condition and severe forms present already in utero. Persons with severe OI is affected throughout their lifetime with repeated, multiple fractures, short stature and orthopaedic problems, considerable pain and handicap. There is no curative or sufficiently effective symptomatic treatment for OI. Preliminary clinical experience indicates that transplantation of fetal liver derived mesenchymal s...

Biographical DetailsCecilia GötherströmCecilia Götherström is Associate Professor in Stem Cell Research at Karolinska Institutet and her research is in the field of perinatal regenerative medicine. She was one of the first in the world to isolate and characterize human fetal mesenchymal stem cells. Dr Götherström has de...

Background: Treatment with multipotent mesenchymal stromal cells (MSC) has the potential to ameliorate mesodermal disorders.Objective: To treat severe osteogenesis imperfecta (OI) with fetal MSC.Methods: Ten years ago, we treated a fetus with OI type III (COL1A2: c.3008G>A, p.Gly1003Asp) in utero with fetal HLA-mismatched MSC. The procedure was uncomplicated. At the age of 4 months i.v. pamidronete treatment was starte...